Table 1 Summarization of ongoing CRISPR related clinical trials
Classification | Identifier | Targeted disease | Targeted gene | Start date | Intervention/treatment | Estimated enrollment | Phase |
|---|---|---|---|---|---|---|---|
CRISPR/Cas9 | NCT02793856 | Metastatic non-small cell lung cancer | Programmed cell death protein 1(PDCD1) gene | August 28, 2016 | Autologous CRISPR Cas9 mediated PD-1 Knockout T cells | 12 | Phase 1 |
NCT03044743 | Advanced Stage EBV Associated Malignancies | PD-1 | April 7, 2017 | CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin | 20 | Phase 1/2 | |
NCT03164135 | HIV-infected Subjects With Hematological Malignances | CCR5 | May 30, 2017 | CD34 + hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene | 5 | – | |
NCT03166878 | Relapsed or Refractory CD19 + Leukemia and Lymphoma | CD19 | June 2017 | Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 | 80 | Phase 1/2 | |
NCT03398967 | Relapsed or Refractory B Cell Leukemia and Lymphoma | CD19 and CD20 or CD22 | January 2, 2018 | Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22 | 80 | Phase 1/2 | |
NCT03545815 | Mesothelin Positive Multiple Solid Tumors | PD-1 and TCR | March 19, 2018 | CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells | 10 | Phase 1 | |
NCT03747965 | Mesothelin Positive Multiple Solid Tumors | PD-1 | November 2018 | CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells | 10 | Phase 1 | |
NCT04417764 | Advanced Hepatocellular Carcinoma | PD-1 | June 20, 2019 | Autologous PD-1 Knockout CRISPR-Cas9-Engineered T Cells | 10 | Phase 1 | |
NCT04035434 | Relapsed or Refractory B-Cell Malignancies | CD19 | July 22, 2019 | CD19-directed Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) | 143 | Phase 1 | |
NCT04244656 | Relapsed or Refractory Multiple Myeloma | BCMA (B-cell maturation antigen) | January 22, 2020 | Anti-BCMA(B-cell maturation antigen) Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) | 80 | Phase 1 | |
NCT04213469 | Relapse/Refractory B-cell Lymphoma | PD1 and CD19 | March 13, 2020 | PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells | 20 | – | |
NCT04426669 | Metastatic Gastrointestinal Epithelial Cancer | CISH (Cytokine-induced SH2 protein) | May 15, 2020 | Autologous CISH (Cytokine-induced SH2 protein) inactivated CRISPR-Cas9-Engineered Tumor-Infiltrating Lymphocytes | 20 | Phase 1/2 | |
NCT04438083 | Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation | CD70 | June 16, 2020 | CD70-directed Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) | 107 | Phase 1 | |
NCT04502446 | Relapsed or Refractory T or B Cell Malignancies | CD70 | July 31, 2020 | Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) | 45 | Phase 1 | |
CRISPR/Cas12 | NCT05447169 | Nasopharyngeal Carcinoma | Epstein-Barr virus DNA | July 10, 2022 | Quantitative polymerase chain reaction and Cas 12a target sequencing of EBV DNA in nasopharyngeal brushing and plasma | 11,625 | – |